Long-term follow-up after receiving CTX001 infusion
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign and date the informed consent form (and assent if it applies).
- If you cannot consent, your legal guardian or authorized representative must consent for you.
- You must have received a CTX001 infusion in the earlier parent study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
This trial tests a single dose of gene therapy (CTX001) to improve outcomes for people with severe sickle cell disease or transfusion-dependent beta-thalassemia. It aims to see how well it works and whether it is safe, especially after a planned stem cell transplant process.
This study follows up on people who have already received the CS-101 infusion in a previous trial. It aims to check how participants are doing over time. There are no restrictions to join if you already received CS-101.
This study checks on participants who previously received the experimental treatment CS-101. It aims to track their health over time to see how safe and effective the treatment is in the long run.
This study is for people who have already received BEAM-101 in a previous study. It simply follows them over time to track their health and any long-term effects.
This study follows up with people who already received the CS-101 injection in a previous trial to check its safety and how well it works over time.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.